FAVONI, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 2.809
AS - Asia 2.756
EU - Europa 1.441
SA - Sud America 214
Continente sconosciuto - Info sul continente non disponibili 124
AF - Africa 112
OC - Oceania 4
Totale 7.460
Nazione #
US - Stati Uniti d'America 2.750
VN - Vietnam 934
SG - Singapore 750
CN - Cina 485
IT - Italia 300
GB - Regno Unito 268
HK - Hong Kong 241
DE - Germania 211
BR - Brasile 161
SE - Svezia 159
FR - Francia 100
IN - India 97
NL - Olanda 96
RU - Federazione Russa 69
IE - Irlanda 54
JO - Giordania 39
ZA - Sudafrica 37
FI - Finlandia 36
BG - Bulgaria 28
CA - Canada 28
KR - Corea 27
BD - Bangladesh 26
NG - Nigeria 25
JP - Giappone 24
PK - Pakistan 23
TH - Thailandia 23
UA - Ucraina 23
AR - Argentina 20
AT - Austria 19
PH - Filippine 19
PL - Polonia 19
CI - Costa d'Avorio 17
MX - Messico 15
EE - Estonia 13
ID - Indonesia 12
IQ - Iraq 11
EC - Ecuador 10
TG - Togo 10
TW - Taiwan 10
ES - Italia 9
BE - Belgio 7
PY - Paraguay 7
UZ - Uzbekistan 6
CL - Cile 5
CO - Colombia 5
CR - Costa Rica 5
LT - Lituania 5
GR - Grecia 4
HU - Ungheria 4
SA - Arabia Saudita 4
SC - Seychelles 4
TR - Turchia 4
AU - Australia 3
CH - Svizzera 3
ET - Etiopia 3
IL - Israele 3
IR - Iran 3
JM - Giamaica 3
KE - Kenya 3
MY - Malesia 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EG - Egitto 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
MT - Malta 2
PE - Perù 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SV - El Salvador 2
TN - Tunisia 2
VE - Venezuela 2
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
GT - Guatemala 1
HT - Haiti 1
LY - Libia 1
MA - Marocco 1
NZ - Nuova Zelanda 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
ST - Sao Tome e Principe 1
TZ - Tanzania 1
UY - Uruguay 1
VG - Isole Vergini Britanniche 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.338
Città #
Singapore 503
Ashburn 305
Ho Chi Minh City 259
San Jose 233
Hanoi 232
Hong Kong 228
Southend 227
Fairfield 213
Santa Clara 179
Woodbridge 123
Chandler 112
Houston 105
Seattle 94
Ann Arbor 91
Princeton 80
Wilmington 80
Cambridge 78
Council Bluffs 75
Beijing 71
Boardman 66
Los Angeles 58
Dublin 54
Hefei 47
Lauterbourg 40
Amman 39
Turin 39
Bologna 37
Da Nang 28
Haiphong 28
New York 28
Sofia 28
Buffalo 26
Abeokuta 25
Redmond 25
Redondo Beach 24
São Paulo 24
Helsinki 23
Westminster 23
Dong Ket 22
Chengdu 21
Milan 21
San Diego 21
Tokyo 21
Berlin 20
Munich 19
Biên Hòa 18
Abidjan 17
Shanghai 17
Nanjing 16
Des Moines 15
Frankfurt am Main 15
Guangzhou 15
Monzuno 14
Seoul 14
Chicago 13
Warsaw 13
Bangkok 12
Dallas 12
Hải Dương 12
Johannesburg 12
Vũng Tàu 12
Ninh Bình 11
Nuremberg 11
Changsha 10
Lomé 10
Phoenix 10
Quận Một 10
Saint Petersburg 10
Shenyang 10
Atlanta 9
Ha Long 9
Hebei 9
Jakarta 9
Nanchang 9
Padova 9
Vienna 9
Brasília 8
Covent Garden 8
Falkenstein 8
Mexico City 8
San Francisco 8
Shenzhen 8
Thái Nguyên 8
Tianjin 8
Brooklyn 7
Brussels 7
Can Tho 7
Dearborn 7
Jacksonville 7
Jiaxing 7
Jinan 7
Lappeenranta 7
Muzaffargarh 7
Quận Bình Thạnh 7
Redwood City 7
The Dalles 7
Wuhan 7
Belo Horizonte 6
Gujranwala 6
Hangzhou 6
Totale 4.640
Nome #
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data 225
Migraine chronification as an allostatic disorder: a proof-of-concept study 225
Central and Peripheral Nervous Disorders 222
Idiopathic intracranial hypertension without papilledema (IIHWOP) in chronic refractory headache 206
Greater Occipital Nerve Infiltration During Pregnancy in Cluster Headache: A Case Report 205
Treatment of withdrawal headache in patients with medication overuse headache: a pilot study 196
A real-world study on unmet medical needs in triptan-treated migraine: Prevalence, preventive therapies and triptan use modification from a large Italian population along two years 195
Vessel-wall MRI in primary headaches: The role of neurogenic inflammation 181
Is physiotherapy in migraines known to sufferers? A cross-sectional study 179
Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study 174
Interobserver reliability of ICSD-3 diagnostic criteria for disorders of arousal in adults 172
Clinical and radiological prognostic factors in spontaneous intracranial hypotension: a case series 172
Cerebrospinal fluid hypocretin-1 levels during the active period of cluster headache. 170
Erenumab efficacy in highly resistant chronic migraine: a real-life study 168
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache 168
Migraine and sleep disorders. 163
Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording 154
State and trait anger and its expression in cluster headache compared with migraine: a cross-sectional study 153
Transverse Sinus Stenosis in Refractory Chronic Headache Patients: An Observational Study 153
CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP? 151
The incidental finding of elevated anti GQ1B antibodies in a patient with selective small fiber neuropathy 149
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache 149
Quality indicators in headache care: an implementation study in six Italian specialist-care centres 144
SUNCT/SUNA and neurovascular compression: New cases and critical literature review. 141
SPARTACUS: underdiagnosis of chronic daily headache in primary care. 141
Recurrent Reversible Cognitive Impairment in a Cluster Headache Patient: A Case Report 140
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center 137
Superficial siderosis associated with peripheral autonomic failure and tetraventricular hydrocephalus: a case report 136
Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare Network 133
Energy Metabolism Impairment in Migraine 132
Migraine and cardiovascular diseases. 132
Idiopathic intracranial hypertension without papilledema in refractory chronic daily headache 132
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) 128
Nociception and autonomic nervous system. 125
Great occipital nerve long-acting steroid injections in cluster headache therapy: an observational prospective study 119
Nummular headache: a gender-oriented perspective on a case series from the RegistRare Network 113
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic 106
Greater occipital nerve blockade in cluster headache: effectiveness and safety of a combined injection protocol 104
Vessel-wall MRI in thunderclap headache: A useful tool to answer the riddle? 104
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study) 101
Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs 100
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance 98
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study 97
P063. Colloid cysts of the third ventricle: a case report 94
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study 91
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study 90
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study 88
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study 87
The ultimate guide to the anti-CGRP monoclonal antibodies galaxy 86
Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study 86
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study 70
An unusual case of anti-basal ganglia encephalitis showing polyradiculoneuritis features 67
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience 67
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study 63
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men 52
Moving closer to the ideal migraine acute treatment 26
Totale 7.460
Categoria #
all - tutte 21.811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.811


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022598 0 16 41 31 63 20 13 85 21 75 142 91
2022/2023681 64 69 23 81 67 43 38 38 144 29 65 20
2023/2024290 10 42 23 47 11 51 24 19 8 29 9 17
2024/20251.286 50 239 90 71 220 65 60 43 11 100 59 278
2025/20263.095 528 206 212 209 289 141 346 208 572 205 97 82
2026/2027172 74 98 0 0 0 0 0 0 0 0 0 0
Totale 7.460